# 510(k) Summary

Date: February 11, 2013

Contact Person: Teffany Hutto

Manufacturer: Encore Medical, L.P. 9800 Metric Blvd Manager, Regulatory Affairs Phone: (512) 834-6255

Austin, TX 78758

Fax: (512) 834-6313 Email: teffany.hutto@djoglobal.com

Product	Classification	Product Code
X-alt <sup>TM</sup> Highly Cross Linked Acetabular Liner with Vitamin E	Class II	LPH - Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis per 21 CFR 888.3358  OQG - Hip prosthesis, semi-constrained, cemented, metal/polymer, + additive, porous, uncemented per 21 CFR 888.3358

<u>Description</u>: A highly cross linked polyethylene acetabular liner infused with pure liquid pharmaceutical grade alpha-tocopheral. The liners are the same dimensions and size offerings as the currently cleared Highly Cross Linked Poly liners (K072154) (28mm, 32mm, 34mm, 36mm, 40mm, and 44mm ID, with neutral, 10° and 20° hooded configurations available in each ID).

## Indications for Use:

Joint replacement is indicated for patients suffering from disability due to:

- noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis of the natural femoral head;
- rheumatoid arthritis;
- correction of functional deformity;
- femoral fracture.

This device may also be indicated in the salvage of previously failed surgical attempts. This device is intended for cementless use only

### Predicate Device:

SEP 2 3 2013

- DJO Surgical X-alt™ Highly Cross Linked Acetabular Liner K072154
- DJO Surgical 3DKnee Tibial Insert with Vitamin E K091956

<u>Comparable Features to Predicate Device(s)</u>: Features comparable to predicate devices include the same design features, materials, indications, sterilization, packaging and intended use.

Non-Clinical Testing: Mechanical testing has demonstrated the device's ability to perform under expected conditions. Testing included mechanical characterization testing, push out, lever out, torsion, rim impingement, fatigue crack propagation, Izod impact, small punch, tensile, FTIR, wear, optical and SEM analysis, wear particle analysis, extraction testing, animal implant for toxilogical response, and cytotoxicity. All testing has determined that the device is substantially equivalent to the predicate devices.

Clinical Testing: None provided.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

## September 23, 2013

Encore Medical, L.P.
Ms. Teffany Hutto
Manager. Regulatory Affairs
9800 Metric Boulevard
Austin, Texas 78758

Re: K130365

Trade/Device Name: X-alt Highly Cross Linked Acetabular Liner with Vitamin E

Regulation Number: 21 CFR 888.3358

Regulation Name: Hip joint metal/polymer/metal semi-constrained porous-coated

uncemented prosthesis

Regulatory Class: Class II Product Code: OQG, LPH Dated: July 15, 2013 Received: July 16, 2013

#### Dear Ms. Hutto:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm">http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</a> for the CDRH's Office

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours.

Erin I. Keith

for

Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if k	nown): K1303	65			
Device Name: X-al	t <sup>TM</sup> Highly Cross Li	nked Acetabulai	Liner with Vitamin E		
Indications for Use:					
X-alo	• •	inked Acetabul adications for U	ar Liner with Vitamin E Jse		
Joint replacement is indicated for patients suffering from disability due to:  noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis of the natural femoral head;  rheumatoid arthritis;  correction of functional deformity;  femoral fracture.					
This device may also	o be indicated in the	salvage of prev	iously failed surgical attempts.		
This device is intend	led for cementless u	se only	·		
Prescription Use (Part 21 CFR 80		AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)		

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Elizabeth L. Frank -S

Division of Orthopedic Devices